JP2010534200A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010534200A5 JP2010534200A5 JP2010516587A JP2010516587A JP2010534200A5 JP 2010534200 A5 JP2010534200 A5 JP 2010534200A5 JP 2010516587 A JP2010516587 A JP 2010516587A JP 2010516587 A JP2010516587 A JP 2010516587A JP 2010534200 A5 JP2010534200 A5 JP 2010534200A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- clec9a
- binding agent
- composition
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 18
- 102000036639 antigens Human genes 0.000 claims 18
- 108091007433 antigens Proteins 0.000 claims 18
- 239000011230 binding agent Substances 0.000 claims 18
- 238000000034 method Methods 0.000 claims 18
- 239000000203 mixture Substances 0.000 claims 13
- 210000004027 cell Anatomy 0.000 claims 12
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 8
- 230000028993 immune response Effects 0.000 claims 8
- 230000004044 response Effects 0.000 claims 8
- 230000001404 mediated effect Effects 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 108020004414 DNA Proteins 0.000 claims 4
- 108010032595 Antibody Binding Sites Proteins 0.000 claims 3
- 206010020751 Hypersensitivity Diseases 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 206010003246 arthritis Diseases 0.000 claims 3
- 210000004443 dendritic cell Anatomy 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 230000004936 stimulating effect Effects 0.000 claims 3
- 238000002054 transplantation Methods 0.000 claims 3
- 108020005544 Antisense RNA Proteins 0.000 claims 2
- 229940123189 CD40 agonist Drugs 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 108090000994 Catalytic RNA Proteins 0.000 claims 2
- 102000053642 Catalytic RNA Human genes 0.000 claims 2
- 102000053602 DNA Human genes 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 108010002352 Interleukin-1 Proteins 0.000 claims 2
- 102000043129 MHC class I family Human genes 0.000 claims 2
- 108091054437 MHC class I family Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 239000003184 complementary RNA Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000000968 medical method and process Methods 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 229930002330 retinoic acid Natural products 0.000 claims 2
- 108091092562 ribozyme Proteins 0.000 claims 2
- 229960001727 tretinoin Drugs 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010057190 Respiratory tract infections Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 108010067390 Viral Proteins Proteins 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 208000026816 acute arthritis Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 238000010322 bone marrow transplantation Methods 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 206010014665 endocarditis Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000002134 immunopathologic effect Effects 0.000 claims 1
- 239000012678 infectious agent Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000000274 microglia Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92999907P | 2007-07-20 | 2007-07-20 | |
| US60/929,999 | 2007-07-20 | ||
| GBGB0805159.1A GB0805159D0 (en) | 2008-03-19 | 2008-03-19 | Immune modulation via C-type lectin |
| GB0805159.1 | 2008-03-19 | ||
| PCT/GB2008/002504 WO2009013484A1 (en) | 2007-07-20 | 2008-07-21 | Immune modulation via c-type lectin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010534200A JP2010534200A (ja) | 2010-11-04 |
| JP2010534200A5 true JP2010534200A5 (enExample) | 2011-09-08 |
| JP5577246B2 JP5577246B2 (ja) | 2014-08-20 |
Family
ID=39356783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010516587A Expired - Fee Related JP5577246B2 (ja) | 2007-07-20 | 2008-07-21 | Ｃ型レクチンを介する免疫 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8580266B2 (enExample) |
| EP (1) | EP2185586B1 (enExample) |
| JP (1) | JP5577246B2 (enExample) |
| CN (1) | CN101896500B (enExample) |
| AU (1) | AU2008278831B2 (enExample) |
| CA (1) | CA2693277A1 (enExample) |
| DK (1) | DK2185586T3 (enExample) |
| ES (1) | ES2557935T3 (enExample) |
| GB (1) | GB0805159D0 (enExample) |
| HR (1) | HRP20160033T1 (enExample) |
| HU (1) | HUE026387T2 (enExample) |
| SI (1) | SI2185586T1 (enExample) |
| WO (1) | WO2009013484A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009026660A1 (en) | 2007-08-30 | 2009-03-05 | Walter And Eliza Hall Institute Of Medical Research | Dendritic cell marker and uses thereof |
| US20110110861A1 (en) * | 2008-05-13 | 2011-05-12 | Mireille Hanna Lahoud | Methods of Detecting Cells with a Disrupted Cell Membrane, Cells Infected with A Pathogen, Dying Cells or Dead Cells |
| JP2012521199A (ja) * | 2009-03-23 | 2012-09-13 | ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ | 免疫応答を調節するための化合物および方法 |
| GB201006768D0 (en) | 2010-04-22 | 2010-06-09 | Cancer Rec Tech Ltd | Method for obtaining dendritic cells |
| CA2798616A1 (en) * | 2010-05-07 | 2011-11-10 | Baylor Research Institute | Dendritic cell immunoreceptors (dcir)-mediated crosspriming of human cd8+ t cells |
| WO2013088136A1 (en) | 2011-12-12 | 2013-06-20 | Ahrens Susan | Ligand for dngr-1 receptor |
| EP2901156B1 (en) * | 2012-09-26 | 2018-06-20 | Cook Biotech Incorporated | Medical device design, manufacture and testing systems |
| US20160015803A1 (en) * | 2014-07-18 | 2016-01-21 | Ross Kedl | Immunostimulatory combinations and use thereof |
| US11478010B2 (en) * | 2014-07-21 | 2022-10-25 | Societe Des Produits Nestle S.A. | Nutritional products to promote safe swallowing for individuals with dysphagia |
| CN104789689B (zh) * | 2015-05-13 | 2018-10-02 | 北京泱深生物信息技术有限公司 | 作为肺腺癌诊治靶标的clec9a基因 |
| US20200079860A1 (en) * | 2015-08-06 | 2020-03-12 | Memorial Sloan Kettering Cancer Center | Methods and compositions for tumor therapy |
| US11661455B2 (en) | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
| CN109071632B (zh) | 2016-02-05 | 2022-12-30 | 奥里尼斯生物科学私人有限公司 | 靶向性治疗剂及其用途 |
| CN105924501B (zh) * | 2016-04-28 | 2019-04-02 | 郑州大学 | 靶向Clec9a的亲和肽WH肽 |
| US11630103B2 (en) | 2016-08-17 | 2023-04-18 | The Broad Institute, Inc. | Product and methods useful for modulating and evaluating immune responses |
| EP3664829A4 (en) | 2017-08-09 | 2021-05-05 | Orionis Biosciences, Inc. | LIAISON OFFICERS AT PD-1 AND PD-L1 |
| CN117924493A (zh) * | 2017-08-09 | 2024-04-26 | 奥里尼斯生物科学有限公司 | Clec9a结合剂及其用途 |
| EP3665201A4 (en) | 2017-08-09 | 2021-06-02 | Orionis Biosciences, Inc. | CD8 BINDERS |
| US12655186B2 (en) | 2018-01-26 | 2026-06-16 | Orionis Biosciences, Inc. | Chimeric protein comprising anti-XCR1 antibody and modified interferon alpha 2 |
| WO2019244973A1 (ja) * | 2018-06-20 | 2019-12-26 | 中外製薬株式会社 | 標的細胞に対する免疫反応を活性化する方法およびその組成物 |
| WO2020041720A1 (en) | 2018-08-24 | 2020-02-27 | Codiak Biosciences, Inc. | Extracellular vesicles targeting dendritic cells and uses thereof |
| EP3890773A4 (en) | 2018-11-08 | 2022-11-09 | Orionis Biosciences, Inc. | MODULATION OF DENDRITIC CELL LINES |
| CA3126039A1 (en) * | 2019-01-08 | 2020-07-16 | University Of Georgia Research Foundation, Inc. | Targeted nanoparticles and their uses related to fungal infections |
| JP7546924B2 (ja) * | 2019-03-01 | 2024-09-09 | 国立大学法人 筑波大学 | アレルギー疾患を処置することに用いるための組成物 |
| CN113840833B (zh) | 2019-03-28 | 2025-06-17 | 奥里尼斯生物科学股份有限公司 | 基于clec9a的嵌合蛋白复合物 |
| CN111544592B (zh) * | 2020-03-13 | 2022-05-03 | 中山大学附属第一医院 | 模式识别受体Dectin-1抑制剂对受体移植物的免疫保护及诱导免疫耐受的应用 |
| EP3892739A1 (en) * | 2020-04-09 | 2021-10-13 | Centre Léon Bérard | Type iii interferon for use as a biomarker to predict response to a cancer treatment |
| GB202011859D0 (en) | 2020-07-30 | 2020-09-16 | Francis Crick Institute Ltd | Cytosolic delivery |
| AU2023255229A1 (en) | 2022-04-21 | 2024-11-14 | The Francis Crick Institute Limited | Bispecific binding agent |
| EP4558225A1 (en) | 2022-07-21 | 2025-05-28 | The Francis Crick Institute Limited | Immunoconjugate |
| GB202401381D0 (en) | 2024-02-02 | 2024-03-20 | Francis Crick Institute Ltd | Anti-actin antibodies |
| WO2026122786A1 (en) * | 2024-12-04 | 2026-06-11 | Henry Ford Health System | Tim-3-targeted vaccines and methods of treating or preventing cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001055448A1 (en) * | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| US20020042386A1 (en) * | 2000-01-31 | 2002-04-11 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
| DE10142994A1 (de) * | 2001-09-01 | 2003-03-27 | Keiper Gmbh & Co | Längseinsteller für einen Fahrzeugsitz |
| WO2003054152A2 (en) * | 2001-12-10 | 2003-07-03 | Nuvelo, Inc. | Novel nucleic acids and polypeptides |
-
2008
- 2008-03-19 GB GBGB0805159.1A patent/GB0805159D0/en not_active Ceased
- 2008-07-21 AU AU2008278831A patent/AU2008278831B2/en not_active Ceased
- 2008-07-21 US US12/669,940 patent/US8580266B2/en not_active Expired - Fee Related
- 2008-07-21 HR HRP20160033TT patent/HRP20160033T1/hr unknown
- 2008-07-21 ES ES08776024.5T patent/ES2557935T3/es active Active
- 2008-07-21 HU HUE08776024A patent/HUE026387T2/en unknown
- 2008-07-21 JP JP2010516587A patent/JP5577246B2/ja not_active Expired - Fee Related
- 2008-07-21 EP EP08776024.5A patent/EP2185586B1/en active Active
- 2008-07-21 SI SI200831558T patent/SI2185586T1/sl unknown
- 2008-07-21 CA CA2693277A patent/CA2693277A1/en not_active Abandoned
- 2008-07-21 CN CN200880107621.2A patent/CN101896500B/zh not_active Expired - Fee Related
- 2008-07-21 DK DK08776024.5T patent/DK2185586T3/en active
- 2008-07-21 WO PCT/GB2008/002504 patent/WO2009013484A1/en not_active Ceased
-
2013
- 2013-10-09 US US14/049,563 patent/US9205153B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260041764A1 (en) | Extracellular vesicles for vaccine delivery | |
| Liu et al. | The immunomodulatory effects of mesenchymal stem cells on regulatory B cells | |
| Wardell et al. | Harnessing the biology of regulatory T cells to treat disease | |
| CN105307725B (zh) | 治疗自身免疫疾病的方法和组合物 | |
| Sun et al. | A single ssDNA aptamer binding to mannose-capped lipoarabinomannan of Bacillus Calmette–Guérin enhances immunoprotective effect against tuberculosis | |
| Jung et al. | Enhanced efficacy of therapeutic cancer vaccines produced by co-treatment with Mycobacterium tuberculosis heparin-binding hemagglutinin, a novel TLR4 agonist | |
| HRP20160033T1 (hr) | Imunološka modulacija preko lectina tipa c | |
| MD3445850T2 (ro) | Metode de obținere a ARN monocatenar | |
| EP3600342B1 (en) | Method for designing rig-i ligands | |
| CA2984485A1 (en) | Nanoparticle compositions for sustained therapy | |
| JP2023515355A (ja) | 高速ワクチンプラットフォーム | |
| CN111373260A (zh) | 产生调节性免疫细胞的方法及其用途 | |
| WO2021189047A2 (en) | Extracellular vesicles for therapy | |
| Romano et al. | A structural view at vaccine development against M. tuberculosis | |
| WO2007139190A1 (ja) | 免疫刺激オリゴヌクレオチド及びその医薬用途 | |
| Horng et al. | HBV X protein-based therapeutic vaccine accelerates viral antigen clearance by mobilizing monocyte infiltration into the liver in HBV carrier mice | |
| Gu et al. | Dectin-1 controls TSLP-induced Th2 response by regulating STAT3, STAT6, and p50-RelB activities in dendritic cells | |
| Ambrożej et al. | “Liquid biopsy”-extracellular vesicles as potential novel players towards precision medicine in asthma | |
| WO2020081730A2 (en) | Methods and compositions for modulating microenvironment | |
| CN111566122A (zh) | 产生用于调控免疫的肽、多肽或细胞的方法 | |
| CN112662695A (zh) | 一种细菌生物膜囊泡（bbv）作为疫苗载体的构建方法和应用 | |
| JP2007521803A (ja) | レギュレーター／サプレッサーｔリンパ球の同定および調製のための方法、その組成物、並びにその使用 | |
| Hanazato et al. | Selection of an aptamer against mouse GP2 by SELEX | |
| US20180256646A1 (en) | Compositions and methods for modulating toll like receptor signal | |
| JP6385732B2 (ja) | 免疫応答制御剤 |